Focus on lymphomas  by Staudt, Louis M. & Wilson, Wyndham H.
F O C U S
CANCER CELL : NOVEMBER 2002 · VOL. 2 · COPYRIGHT © 2002 CELL PRESS 363
Epidemiology
Lymphomas comprise the fifth most common cancer type in the
United States, with approximately 55,000 cases of non-
Hodgkin’s lymphoma (NHL) and 7,400 cases of Hodgkin’s lym-
phoma (HL) each year. An unexplained finding is the 80% rise in
NHL between 1973 and 1997 (http://www.seer.cancer.gov).The
strongest known risk factors are genetic and acquired immun-
odeficiencies (Knowles, 1999). Epstein-Barr virus (EBV) is an
important cofactor in the development of B cell lymphoma
among immunosuppressed patients, but also plays a role in
immunocompetent patients with Burkitt’s lymphoma and HL.
Human herpes virus 8 and human T-lymphotropic virus-1 are
associated with primary effusion lymphoma and peripheral T
cell lymphoma, respectively. Chronic immune stimulation by H.
pylori is an etiologic factor in gastric MALT lymphoma
(Wotherspoon et al., 1993). Autoimmune conditions such as
Sjogren’s syndrome are associated with an excess risk of mar-
ginal zone lymphomas (Mariette, 1999).
Molecular pathogenesis of lymphomas
Diverse molecular abnormalities in lymphomas converge on
common pathways that promote proliferation, block differentia-
tion, inhibit cell death, or permit genomic instability (Figure 1).
Chromosomal translocations are frequent oncogenic events in
lymphomas and can be aberrant byproducts of the molecular
machinery that remodels the immunoglobulin (Ig) loci during
normal lymphocyte differentiation (Kuppers and Dalla-Favera,
2001). Typically, these translocations do not alter the coding
region of the oncogene at the translocation breakpoint, but
rather deregulate its expression.
Molecular cloning of the recurrent t(14;18) translocation in
follicular lymphoma (FL) led to the discovery of BCL-2 and to an
appreciation that cancer cells frequently evade apoptosis (Chao
and Korsmeyer, 1998). Antiapoptotic members of the BCL-2
family are overexpressed in many lymphomas due to chromoso-
mal translocation or amplification, or by transcriptional activation
(Figure 1). Exceedingly high BCL-2 expression is characteristic
of small lymphocytic lymphoma/chronic lymphocytic leukemia
(SLL/CLL) and mantle cell lymphoma (MCL), but the mecha-
nisms underlying this transcriptional overexpression are
unknown. In other lymphomas, apoptosis can be blocked by the
NF-κB signaling pathway (Baldwin, 2001). Normally, NF-κB tran-
scription factors are sequestered in the cytoplasm by IκΒα.
Signaling through various receptors activates IκB kinase (IKK) to
phosphorylate IκBα, leading to its degradation in the proteo-
some and the release of NF-κB to the nucleus. In lymphomas,
the NF-κB pathway can be abnormally activated by transloca-
tions involving the NFkB2, BCL10, and MALT1 genes, by IκBα
mutations or deletions, and by activation of IKK by viruses or
intracellular signaling pathways that have not been fully charac-
terized (Figure 1).
Roughly one-sixth of all NHLs have translocations of BCL-6,
which encodes a transcriptional repressor required for the
development and function of normal germinal center (GC) B
cells (Dalla-Favera et al., 1999; Staudt et al., 1999). BCL-6
blocks terminal differentiation of GC B cells to plasma cells by
repressing Blimp-1 (Shaffer et al., 2000). BCL-6 translocations
may therefore cause lymphomas by trapping cells at the GC
stage of differentiation, exposing them to the potentially muta-
genic effects of the Ig somatic hypermutation apparatus
(Pasqualucci et al., 2001). BCL-6 can also block cellular senes-
cence (Shvarts et al., 2002) and repress transcription of the
cyclin-dependent kinase inhibitor p27kip1 (Shaffer et al., 2000),
which may extend the replicative capacity of cells with BCL-6
translocations.
Cell growth and proliferation is deregulated in various lym-
phomas by translocation, mutation, and overexpression of c-myc
(Figure 1). Likewise, G1-S phase progression can be promoted
by translocation or overexpression of the genes encoding D-type
cyclins. The senescence checkpoint that limits proliferation may
be abrogated in mantle cell lymphoma (MCL) by genomic dele-
tion of p16INK4A or by genomic amplification of bmi-1, which
encodes a repressor of the INK4A locus (Bea et al., 2001).
An important acquired trait of lymphomas is functional inac-
tivation of genes that monitor genome integrity. ATM, which
senses DNA damage and telomere integrity, is frequently inacti-
vated by genomic deletions and mutations in MCL (Schaffner et
al., 2000). Inactivation of p53 occurs in many lymphomas and is
associated with adverse outcome in MCL (Louie et al., 1995)
and with transformation of FL to diffuse large B cell lymphoma
(DLBCL) (Lo Coco et al., 1993; Sander et al., 1993).
Molecular diagnosis of lymphomas
The standard for the pathological identification of lymphomas is
the World Heath Organization (WHO) classification, which inte-
grates tumor morphology, immunophenotype, recurrent genetic
abnormalities, and clinical features (Supplemental Table S1 at
http://www.cancercell.org/cgi/content/full/2/5/363/DC1) (Jaffe et
al., 2001). This classification recognizes over 30 different lym-
phoma types derived from virtually every stage of normal lym-
phocyte differentiation and has proven useful in patient man-
agement and treatment. Nonetheless, clinical outcomes of
patients assigned to the same diagnostic category can be quite
heterogeneous. For instance, the survival of patients with follic-
ular lymphoma can range from 20 years to less than 1 year. In
DLBCL, roughly 40% of patients are cured by multiagent
chemotherapy, whereas the others succumb to this disease.
Such clinical heterogeneity often stems from molecular dif-
ferences between tumors. For example, gene expression profil-
ing has revealed that DLBCL is comprised of molecularly dis-
tinct subgroups that are derived from different stages of normal
B cell differentiation and have different cure rates (Figure 2A)
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(Alizadeh et al., 2000; Rosenwald et al., 2002). Roughly half of
the DLBCL tumors express genes that are characteristic of nor-
mal GC B cells, and this subgroup has been termed germinal
center B cell-like (GCB) DLBCL. Another ?30% of DLBCL
tumors lack expression of these genes, but instead express
genes characteristic of mitogenically activated peripheral blood
B cells, and this subgroup has been termed activated B cell-like
(ABC) DLBCL. Finally, ?20% of DLBCL tumors do not resemble
either GCB or ABC DLBCL in gene expression, and this hetero-
geneous subgroup has been termed Type 3 DLBCL. Clinically,
patients with GCB DLBCL have the best prognosis (Figure 2A).
Analysis of recurrent chromosomal aberrations demonstrat-
ed that the DLBCL gene expression subgroups can be consid-
ered pathogenetically distinct diseases. BCL-2 translocations
and c-rel amplifications occur only in GCB DLBCLs (Rosenwald
et al., 2002). Conversely, ABC DLBCLs utilize the antiapoptotic
NF-κB pathway by constitutive activation of the IKK (Davis et al.,
2001).
The DLBCL gene expression subgroup distinction explains
some, but not all, of the variable survival of these patients. Clinical
outcome data were used to discover genes whose expression
patterns correlate with survival following chemotherapy for
DLBCL, and these genes were combined to form multivariate
predictors of survival (Rosenwald et al., 2002; Shipp et al., 2002).
Clinical parameters also predict survival
(INHLPFP, 1993), but the gene expres-
sion-based predictors were independent
of the clinical predictor. Thus, the effec-
tiveness of chemotherapy in DLBCL is
dictated both by intrinsic molecular prop-
erties of DLBCL tumors and by clinical
features of these patients, such as the
extent of tumor bulk at diagnosis.
Four variable biological features of
DLBCL tumors have the most influence
on clinical outcome, and these biological
features are reflected in characteristic
gene expression signatures (Figure 2B)
(Rosenwald et al., 2002). The GC B cell
gene expression signature predicts favor-
able survival, in keeping with the relative-
ly favorable course of GCB DLBCL
patients. The proliferation gene expres-
sion signature, which reflects the rate of tumor cell division, pre-
dicts poor outcome. The expression of major histocompatibility
complex class II genes predicts favorable survival, as do genes
in the lymph node signature, which reflects a reactive stromal
and innate immune response to the DLBCL tumor cells.The pre-
dictive power of these two gene expression signatures suggests
that the immune response to the DLBCL cells may be an impor-
tant determinant of overall survival following chemotherapy.
Recent treatment advances
Lymphomas, being malignancies of immune cells, are usually
systemic and require chemotherapy. Some lymphoma types are
potentially curable, whereas others may respond to therapy but
are incurable (Supplemental Table S1). In DLBCL, the most
common curable lymphoma, the addition of rituximab, a mono-
clonal antibody against CD20, to standard CHOP chemothera-
py has significantly increased the survival and probable cure of
older patients (Coiffier et al., 2002). Dose-adjusted EPOCH, a
rationally designed chemotherapy based on principals of phar-
macodynamics and drug resistance, may be more effective in
highly proliferative DLBCLs (Wilson et al., 2002).
Monoclonal antibodies are also effective in other lymphoma
types. Rituximab alone or in combination with chemotherapy has
improved the treatment outcome of low-grade B cell lymphomas
Figure 1. Pathogenetic mechanisms in lym-
phomas
Arrows indicate presumptive target genes and
pathways affected by oncogenic events in vari-
ous lymphoma types. An enhanced version of
this figure with references is available as
Supplemental Figure S1 at http://www.cancer
ce l l .o rg/cg i/content/ fu l l /2/5/363/DC1.
Abbreviations: BL, Burkitts lymphoma; DLBCL,
diffuse large B cell lymphoma; ABC, activated B
cell; MCL, mantle cell lymphoma; B-NHL, B cell
non-Hodgkins lymphoma; LPCL, lymphoplas-
macytoid lymphoma; FL, follicular lymphoma,
GCB, germinal center B cell; SLL, small lympho-
cytic lymphoma; CLL, chronic lymphocytic
leukemia; CTCL, cutaneous T cell lymphoma;
MZL, marginal zone lymphoma; HD, Hodgkins
disease; EBV, Epstein-Barr virus; PTLD, posttrans-
plant lymphoproliferative disorder; ATL, adult T
cell lymphoma; ALCL, anaplastic large cell lym-
phoma.
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(Czuczman et al., 1999; Maloney et al., 1997). Alemtuzumab, a
monoclonal antibody against the CD52 antigen, achieved a 33%
response rate in refractory CLL and a 60% complete response
rate in T cell prolymphocytic leukemia (Keating et al., 2002).
Immunotoxin fusion proteins are also promising. A fusion of diph-
theria toxin and interleukin-2 is effective in 30% of cutaneous T
cell lymphomas (Olsen et al., 2001), and a fusion of an anti-
CD22 variable domain with pseudomonas exotoxin induces
complete remissions in patients with resistant hairy-cell
leukemia (Kreitman et al., 2001).
Augmentation of immunity against lymphomas is another
promising approach. Vaccines using Ig idiotype-keyhole limpet
hemocyanin conjugates or Ig idiotype-pulsed dendritic cells pro-
duce clinical responses and could be potentially curative in FL
(Bendandi et al., 1999; Timmerman et al., 2002).
Eradication of an infectious agent can be curative in some
lymphomas. More than half of patients with gastric MALT lym-
phoma can be cured by antibiotic treatment of H. pylori
(Wotherspoon et al., 1993). Treatment of hepatitis C with inter-
feron α can cure some patients with splenic lymphoma with vil-
lous lymphocytes (Hermine et al., 2002).
Future challenges in the lymphomas
An intriguing new therapeutic target
in several lymphoma types is the
NF-κB pathway (Figure 2). Inhibition
of this pathway is lethal to cell line
models of ABC DLBCL (Davis et al.,
2001), HL (Bargou et al., 1997), and
EBV-associated lymphoproliferative
disorders (Cahir-McFarland et al.,
2000). An inhibitor of the proteo-
some, velcade/PS-341, blocks the
NF-κB pathway and has been used
successfully in Phase II clinical tri-
als of multiple myeloma (Adams,
2002). This agent could have activity
in certain lymphomas as a single
agent, and could synergize with con-
ventional chemotherapy, given that
the NF-κB pathway blocks the induction of apoptosis by
DNA damaging agents (Baldwin, 2001).
Therapeutic strategies targeting BCL-2 are promising,
given its frequent overexpression in lymphomas. One approach
involves antisense inhibition of BCL-2 (Waters et al., 2000).
Future strategies may exploit the fact that BCL-2 uses its BH3
domain to bind proapoptotic BH3-only proteins, preventing
them from interacting with BAX/BAK and initiating apoptosis
(Letai et al., 2002). BH3 mimetics could conceivably fill the BCL-
2 BH3 pocket, thus sensitizing tumor cells to the apoptotic
action of BH3-only proteins.
We must remember that the lymphomas constitute a
diverse collection of diseases, and that successful therapy will
depend on detailed knowledge of the pathogenetic pathways
involved in each lymphoma. Given the clinical and molecular
heterogeneity within the current diagnostic categories of lym-
phomas, it will be essential to refine lymphoma diagnosis by
including quantitative molecular assays based on the results of
gene expression profiling. Such efforts will certainly add to the
large number of potential molecular targets in the lymphomas
that have already been defined.
Figure 2. Molecular diagnosis of diffuse large B
cell lymphoma (DLBCL)
A: Subgroups of DLBCL defined by hierarchical
clustering of gene expression data have distinct
clinical and pathogenetic features (Davis et al.,
2001; Rosenwald et al., 2002). Relative gene
expression is depicted on a color scale in which
red represents higher expression, green repre-
sents lower expression, and black represents
median expression. Each column represents a
different lymphoma biopsy sample, and each
row a different gene. 
B: A gene expression-based outcome predictor
of survival following chemotherapy for DLBCL
based on four gene expression signatures (see
text for details) and the expression of a single
gene, BMP6 (Rosenwald et al., 2002). High
expression of a predictor component in a DLBCL
tumor correlated with favorable or poor survival
as indicated. Patients with DLBCL were assigned
an outcome predictor score based on these 5
gene expression variables. The patients were
ranked according to their outcome predictor
scores and divided into 4 quartiles that are rep-
resented by different colors in the Kaplan-Meier
plot of overall survival.
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